Center-Authored Papers

Filters: Author is Urban, Nicole  [Clear All Filters]
Journal Article
Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O'Briant K, Schummer M, Karlan B, Urban ND, Tewari M et al..  2010.  Activation of the MEK-S6 pathway in high-grade ovarian cancers.. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 18(6):499-508. Abstract
Strauss R, Li Z-Y, Liu Y, Beyer I, Persson J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P et al..  2011.  Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity.. PloS one. 6(1):e16186. Abstract
Chen A, Kozak D, Battersby BJ, Forrest RM, Scholler N, Urban ND, Trau M.  2009.  Antifouling surface layers for improved signal-to-noise of particle-based immunoassays.. Langmuir : the ACS journal of surfaces and colloids. 25(23):13510-5. Abstract
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
Schummer M, Beatty JD, Urban ND.  2010.  Breast cancer genomics: normal tissue and cancer markers.. Annals of the New York Academy of Sciences. 1210:78-85. Abstract
Andersen MR, Thorpe J, Buist DSM, Beatty JD, Watabayashi K, Hanson N, Resta R, Chubak J, Urban ND.  2014.  Cancer risk awareness and concern among women with a family history of breast or ovarian cancer.. Behavioral medicine (Washington, D.C.). Abstract
Etzioni R, Urban ND, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L.  2003.  The case for early detection.. Nature reviews. Cancer. 3(4):243-52. Abstract
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al..  2008.  Circulating microRNAs as stable blood-based markers for cancer detection.. Proceedings of the National Academy of Sciences of the United States of America. 105(30):10513-8. Abstract
Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban ND.  2008.  Combining a symptoms index with CA 125 to improve detection of ovarian cancer.. Cancer. 113(3):484-9. Abstract
Schummer M, Green A, Beatty JD, Karlan BY, Karlan S, Gross J, Thornton S, McIntosh MW, Urban ND.  2010.  Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection.. PloS one. 5(2):e9122. Abstract
Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang S-W, Podratz K, Urban ND, Dowdy SC.  2011.  Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.. Gynecologic oncology. 124(20):270-275. Abstract
Bós AM, Howard BV, Beresford SAA, Urban ND, Tinker LF, Waters H, Bós AJ, Chlebowski R, Ennis JM.  2011.  Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer.. Journal of the American Dietetic Association. 111(1):56-66. Abstract
Urban ND.  2011.  Designing early detection programs for ovarian cancer.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22 Suppl 8:viii6-viii18. Abstract
Wang H, Li Z-Y, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang X-B et al..  2011.  Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.. Nature medicine. 17(1):96-104. Abstract
Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, Xi L, Drescher CW, Urban ND, Kiviat N.  2008.  DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.. Gynecologic oncology. 111(2):320-9. Abstract
Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO et al..  2010.  DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.. PloS one. 5(2):e9359. Abstract
Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban ND, Gambhir SS.  2011.  Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology. 259(2):329-45. Abstract
Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N et al..  2016.  The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.. Cancer. 122(22):3509-3518. Abstract
Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh MW, Andersen MR, Scholler N, Bergan L, Thorpe J et al..  2008.  Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 17(9):2480-7. Abstract
Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Möller T, Wildner O, Pesonen S et al..  2009.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.. Cancer research. 69(12):5115-25. Abstract
Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban ND, Henke M, Blau AC.  2009.  Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.. Stem cells (Dayton, Ohio). 27(9):2353-61. Abstract
Schummer M, Thorpe J, Giraldez M, Bergan L, Tewari M, Urban ND.  2015.  Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.. PloS one. 10(11):e0142911. Abstract
Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, Hellström KE, Urban ND.  2012.  Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.. Gynecologic oncology. 125(1):65-69. Abstract
Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban ND, Mor G, Bast RC, Moore LE et al..  2011.  A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.. Cancer prevention research (Philadelphia, Pa.). 4(3):375-83. Abstract
Lin D-C, Xu L, Ding L-W, Sharma A, Liu L-Z, Yang H, Tan P, Vadgama J, Karlan BY, Lester J et al..  2013.  Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.. Proceedings of the National Academy of Sciences of the United States of America. 110(15):6109-14. Abstract